Companion diagnostics is gaining currency as novel drugs are being paired up with tests that determine which patients will have a higher chance of responding to that drug.
But 15 years after the human genome project has been completed, the progress of precision medicine appears to be woefully slow, at least according to Nicholas Dracopoli, vice president and head of Oncology Biomarkers at Janssen Research & Development, part of Johnson & Johnson. Others believe precision medicine and companion diagnostics have a chicken and egg problem.